NCT01267955 2026-03-18
Vismodegib in Treating Patients With Advanced Chondrosarcomas
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
23 trialsNCT03498521 2025-11-19
CUPISCO
Hoffmann-La Roche
Phase 2 Completed
NCT01064622 2024-11-19
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT02091141 2024-07-23
My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors
Genentech, Inc.
Phase 2 Completed
NCT01835626 2021-05-03
Phase II Study of Radiation Therapy and Vismodegib for Advanced Head/Neck Basal Cell Carcinoma
University of California, San Francisco
Phase 2 Completed
NCT02366312 2021-02-18
KCOT
NYU College of Dentistry
Phase 2 Completed
NCT00957229 2021-01-11
GDC-0449
UCSF Benioff Children's Hospital Oakland
Phase 2 Completed
NCT00887159 2021-01-05
A Randomized Phase II Study of Cisplatin and Etoposide in Combination With Either Hedgehog Inhibitor GDC-0449 or IGF-1R MOAB IMC-A12 for Patients With Extensive Stage
National Cancer Institute (NCI)
Phase 2 Completed
NCT01556009 2020-11-02
Vismodegib
UCSF Benioff Children's Hospital Oakland
Phase 2 Completed
NCT02067104 2019-08-14
Vismodegib in Basal Cell Carcinomas (BCC) Chemoprevention
University of Arizona
Phase 2 Terminated
NCT01700049 2019-05-23
Study Evaluating the Efficacy of Oral Vismodegib in Various Histologic Subtypes
Mayo Clinic
Phase 2 Completed
NCT01088815 2019-04-26
Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT01815840 2017-09-28
A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas
Hoffmann-La Roche
Phase 2 Completed
NCT00636610 2017-06-08
A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) With Concurrent Chemotherapy and Bevacizumab As First-Line Therapy for Metastatic Colorectal Cancer
Genentech, Inc.
Phase 2 Completed
NCT00739661 2017-06-08
A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) As Maintenance Therapy in Patients With Ovarian Cancer in a Second or Third Complete Remission
Genentech, Inc.
Phase 2 Completed
NCT01898598 2017-05-08
A Study of Vismodegib With Surgery in Participants With Previously Untreated Basal Cell Carcinoma
Hoffmann-La Roche
Phase 2 Terminated
NCT00982592 2016-01-25
Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT01239316 2016-01-14
Vismodegib in Treating Younger Patients With Recurrent or Refractory Medulloblastoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT01880437 2015-12-15
A Study of Vismodegib in Patients With Relapsed/Refractory Acute Myelogenous Leukemia and Relapsed Refractory High-Risk Myelodysplastic Syndrome
Hoffmann-La Roche
Phase 2 Terminated
NCT00833417 2015-05-20
A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) in Patients With Advanced Basal Cell Carcinoma
Genentech, Inc.
Phase 2 Completed
NCT00959647 2015-01-07
A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study
Genentech, Inc.
Phase 2 Completed
NCT01543581 2014-09-26
Erivedge
Loma Linda University
Phase 2 Completed
NCT01201915 2014-06-24
A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma
Genentech, Inc.
Phase 2 Completed